ARMR Sciences Inc., a biodefense technology company, announced the completion of a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent. The funding will support the continued development and clinical progression of its fentanyl vaccine, which is designed to prevent fatal overdoses and address threats from synthetic drugs like fentanyl. The vaccine is backed by early-stage research funding from the U.S. Department of Defense, as noted in the company’s press release.
The vaccine represents a critical shift in national strategy: from reacting to overdoses to preventing them at the source. According to ARMR, fentanyl is the #1 killer of U.S. adults aged 18 to 45. This long-acting, preventive immunotherapy aims to stop synthetic drug overdose before it begins, starting with fentanyl. The company’s foundational license and backing from the U.S. Department of War underscore the national security implications of this development.
Qualified prospective investors who meet the qualifications of an “accredited investor” can invest $5,000 in this offering and become a shareholder and owner of ARMR, according to the announcement. The private placement is a key step toward advancing the vaccine into human trials.
For more information, visit the company’s website at https://armrsciences.com/ or view the full announcement at https://ibn.fm/t39w2.
The announcement was disseminated by BioMedWire, a specialized communications platform focusing on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, article syndication, press release enhancement, social media distribution, and tailored corporate communications solutions.
BioMedWire is based in Austin, Texas, and can be reached at 512.354.7000 or via email at Editor@BioMedWire.com. Full terms of use and disclaimers are available on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement Led by Joseph Gunnar & Co..